

Statement of Standalone and Consolidated Financial Results for the quarter and year ended 31 March 2026

Sl. No	Particulars	Standalone				Consolidated							
		Quarter ended		Year ended		Quarter ended		Year ended					
		31 March 2026 (Audited) (Refer note 8)	31 December 2025 (Unaudited)	31 March 2025 (Audited) (Refer note 8)	31 March 2026 (Audited)	31 March 2025 (Audited)	31 March 2026 (Audited) (Refer note 8)	31 March 2025 (Audited) (Refer note 8)	31 March 2026 (Audited)				
1	<b>Income</b>												
	(a) Revenue from operations	33,219	29,018	20,324	1,50,721	1,25,189	36,095	20,143	1,58,446	1,23,452			
	(b) Other income	310	151	232	809	988	161	62	281	804			
	<b>Total Income</b>	<b>33,529</b>	<b>29,169</b>	<b>20,556</b>	<b>1,51,530</b>	<b>1,26,177</b>	<b>36,256</b>	<b>20,205</b>	<b>1,58,727</b>	<b>1,24,256</b>			
2	<b>Expenses</b>												
	(a) Cost of raw materials and packing materials consumed	20,219	14,731	16,890	1,02,767	83,522	22,302	16,287	1,07,597	78,909			
	(b) Purchases of traded goods	130	787	12	2,875	4,630	131	13	2,900	4,641			
	(c) Changes in inventories of finished goods, work-in-progress and traded goods	2,439	4,278	12	(2,167)	7,499	2,196	235	(2,806)	7,679			
	(d) Employee benefits expense	3,949	3,644	3,771	15,192	13,993	4,174	3,989	16,057	14,792			
	(e) Finance costs	699	982	942	3,725	4,948	721	1,395	6,449	6,495			
	(f) Depreciation and amortisation expense	5,594	4,767	542	2,133	1,930	886	804	3,196	2,905			
	(g) Other expenses	33,648	29,715	28,979	1,47,522	1,38,753	36,375	29,728	1,56,009	23,718			
	<b>Total Expenses</b>	<b>(119)</b>	<b>(546)</b>	<b>(8,423)</b>	<b>4,008</b>	<b>(12,576)</b>	<b>(119)</b>	<b>(9,523)</b>	<b>2,718</b>	<b>(14,883)</b>			
3	<b>Profit / (loss) before share of profit / (loss) of associate and exceptional items (1-2)</b>												
4	Share of profit / (loss) from associate	(119)	(546)	(8,423)	4,008	(12,576)	(119)	27	(16)	33			
5	<b>Profit / (loss) before exceptional items and tax (3+4)</b>												
6	Exceptional items (refer note 4)	(119)	(546)	(5,497)	(1,028)	2,926	(119)	2,926	(1,745)	2,926			
7	<b>Profit / (loss) before tax (5+6)</b>												
8	Tax expense / (credit):												
	(a) Current tax	(43)	(206)	(1,386)	706	(2,342)	(27)	(6)	499	1			
	(b) Deferred tax	(43)	(206)	(1,386)	706	(2,342)	(33)	(1,570)	500	(2,712)			
	<b>Total tax expense / (credit)</b>	<b>(76)</b>	<b>(340)</b>	<b>(4,111)</b>	<b>2,274</b>	<b>(7,308)</b>	<b>(86)</b>	<b>(5,000)</b>	<b>457</b>	<b>(9,213)</b>			
9	<b>Net Profit / (loss) after tax (7-8)</b>												
10	<b>Other Comprehensive income / (loss)</b>												
	Items that will not be reclassified subsequently to statement of profit or loss												
	Re-measurement of the defined benefit obligation	39	12	(366)	(21)	(405)	46	(368)	(14)	(405)			
	Income tax expense on the above	(10)	(3)	92	5	102	(11)	92	4	102			
	Effective portion of gain/ (loss) on designated portion of hedging instrument in a cash flow hedge	-	-	-	-	(21)	-	-	-	(21)			
	Income tax expense on the above	-	-	-	-	5	-	-	-	5			
	<b>Total Other Comprehensive income / (loss), net of tax</b>	<b>29</b>	<b>9</b>	<b>(274)</b>	<b>(16)</b>	<b>(319)</b>	<b>35</b>	<b>(276)</b>	<b>(10)</b>	<b>(319)</b>			
11	<b>Total Comprehensive income / (loss) (9+10)</b>	<b>(47)</b>	<b>(331)</b>	<b>(4,385)</b>	<b>2,258</b>	<b>(7,627)</b>	<b>(51)</b>	<b>(5,276)</b>	<b>447</b>	<b>(9,532)</b>			
12	Paid-up equity share capital (Face value of ₹ 1 per equity share)	2,342	2,340	2,012	2,342	2,012	2,342	2,012	2,342	2,012			
13	Other Equity				71,198	44,136			65,950	40,694			
14	Earnings Per Share (of ₹ 1 each) for the period, not annualised)	(0.03)	(0.16)	(1.90)	1.04	(3.39)	(0.04)	(2.31)	0.21	(4.27)			
	(a) Basic (in ₹)	(0.03)	(0.16)	(1.90)	1.04	(3.39)	(0.04)	(2.31)	0.21	(4.27)			
	(b) Diluted (in ₹)	(0.03)	(0.16)	(1.90)	1.04	(3.39)	(0.04)	(2.31)	0.21	(4.27)			



**Audited Standalone and Consolidated Balance Sheet**

(₹ in Lakhs)

Sl. No.	Particulars	Standalone		Consolidated	
		As at 31 March 2026	As at 31 March 2025	As at 31 March 2026	As at 31 March 2025
<b>I</b>	<b>ASSETS</b>				
1	<b>Non-current assets</b>				
	(a) Property, plant and equipment	23,528	23,080	40,442	39,495
	(b) Capital work-in-progress	496	724	671	2,152
	(c) Intangible assets	1,023	705	1,023	705
	(d) Intangible assets under development	1,137	2,116	1,137	2,116
	(e) Right-of-use assets	1,046	262	4,435	3,702
	(f) Investments accounted for using the equity method			816	1,549
	(g) Financial assets				
	(i) Investments	26,932	11,437	1	1
	(ii) Loans	82	76	-	-
	(iii) Other non-current financial assets	598	538	744	683
	(h) Deferred tax assets (net)	2,387	3,088	3,331	3,826
	(i) Income tax assets (net)	622	1,163	636	1,135
	(j) Other non-current assets	267	228	706	355
	<b>Total non-current assets</b>	<b>58,118</b>	<b>43,417</b>	<b>53,942</b>	<b>55,719</b>
2	<b>Current assets</b>				
	(a) Inventories*	26,354	26,240	28,258	27,360
	(b) Financial assets				
	(i) Trade receivables*	46,846	31,367	45,836	27,496
	(ii) Cash and cash equivalents	211	5,718	269	5,731
	(iii) Other balances with banks	3,191	203	3,192	204
	(iv) Loans	-	2,093	-	-
	(v) Other current financial assets	834	774	-	-
	(c) Other current assets*	2,535	3,037	4,896	5,785
	<b>Total current assets</b>	<b>79,971</b>	<b>69,432</b>	<b>82,451</b>	<b>66,576</b>
	<b>Total Assets</b>	<b>1,38,089</b>	<b>1,12,849</b>	<b>1,36,393</b>	<b>1,22,295</b>
<b>II</b>	<b>EQUITY AND LIABILITIES</b>				
1	<b>Equity</b>				
	(a) Equity share capital	2,342	2,012	2,342	2,012
	(b) Other equity	71,198	44,136	65,950	40,694
	<b>Total equity</b>	<b>73,540</b>	<b>46,148</b>	<b>68,292</b>	<b>42,706</b>
2	<b>Non-current liabilities</b>				
	(a) Financial liabilities				
	(i) Borrowings	-	968	-	8,462
	(ii) Lease liabilities	949	154	949	154
	(iii) Other financial liabilities	-	29	-	-
	(b) Provisions	2,381	2,230	2,425	2,267
	<b>Total non-current liabilities</b>	<b>3,330</b>	<b>3,381</b>	<b>3,374</b>	<b>10,883</b>
3	<b>Current Liabilities</b>				
	(a) Financial liabilities				
	(i) Borrowings	30,113	26,818	30,118	31,132
	(ii) Lease liabilities	129	119	129	119
	(iii) Trade payables*				
	(a) total outstanding dues of micro enterprises and small enterprises	2,780	5,809	3,715	6,233
	(b) total outstanding dues of creditors other than micro enterprises and small enterprises	22,353	22,769	24,708	23,237
	(iv) Other financial liabilities*	4,025	3,106	4,159	3,260
	(b) Provisions	555	660	563	664
	(c) Current tax liabilities (net)	106	149	106	109
	(d) Other current liabilities	1,158	3,890	1,229	3,952
	<b>Total current liabilities</b>	<b>61,219</b>	<b>63,320</b>	<b>64,727</b>	<b>68,706</b>
	<b>Total liabilities</b>	<b>64,549</b>	<b>66,701</b>	<b>68,101</b>	<b>79,589</b>
	<b>Total equity and liabilities</b>	<b>1,38,089</b>	<b>1,12,849</b>	<b>1,36,393</b>	<b>1,22,295</b>

\* During the year, in view of improved presentation, the Company has reassessed presentation of following in standalone and consolidated financial statements:

1. Rebates to customers and provision for sales returns, have been adjusted against "trade receivables", which were earlier included in "other financial liabilities" amounting to ₹ 5,040 lakhs as at 31 March 2026 (₹ 4,015 lakhs as at 31 March 2025).
2. Accrued salaries and wages to employees have been reclassified under "Other financial liabilities" which were earlier included in trade payables amounting to ₹ 352 lakhs as at 31 March 2026 (₹ 157 lakhs as at 31 March 2025).
3. Right to return assets have been reclassified under "Inventories" which were earlier included in "Other current assets" amounting to ₹ 541 lakhs as at 31 March 2026 (₹ 748 lakhs as at 31 March 2025).



Audited Standalone and Consolidated statement of Cash Flows

(₹ in lakhs)

Particulars	Standalone		Consolidated	
	31 March 2026	31 March 2025	31 March 2026	31 March 2025
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>				
Profit / (loss) before tax	2,980	(9,650)	957	(11,924)
<b>Adjustments for:</b>				
Depreciation and amortisation expense	2,133	1,930	3,196	2,905
Finance costs	3,725	4,948	4,649	6,495
Gain on termination of lease	(13)	-	(13)	-
Interest income under the effective interest method	(453)	(304)	(132)	(295)
Exceptional item	1,028	-	1,745	(2,926)
Share of profit from associate	-	-	16	(33)
Impairment allowances on trade receivables	2,985	4,266	2,985	4,266
Net loss on disposal of property, plant and equipment	51	62	51	62
Impairment of non-current assets	200	298	200	298
Share-based payments	64	42	64	42
Unwinding of Guarantee commission	(62)	(45)	-	-
Unrealised forex (gain) / loss	(118)	(43)	(113)	(43)
<b>Operating profit / (loss) before working capital changes</b>	<b>12,520</b>	<b>1,504</b>	<b>13,605</b>	<b>(1,153)</b>
<b>Working capital adjustments</b>				
Decrease/ (Increase) in Inventories	(114)	7,751	(898)	12,196
Decrease/ (Increase) in Trade receivables	(18,036)	38,456	(20,897)	35,665
Decrease/ (Increase) in Other assets	323	4,151	483	144
(Decrease)/ Increase in Trade payables	(3,730)	(2,180)	(1,337)	(3,282)
(Decrease)/ Increase in Provisions	25	441	43	459
(Decrease)/ Increase in Other liabilities	(2,004)	(5,143)	(1,972)	2,979
<b>Cash generated from / (used in) operations</b>	<b>(11,016)</b>	<b>44,980</b>	<b>(10,973)</b>	<b>47,008</b>
Income taxes paid (net)	595	(113)	559	(110)
<b>Net cash flow generated from / (used in) operating activities (A)</b>	<b>(10,421)</b>	<b>44,867</b>	<b>(10,414)</b>	<b>46,898</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>				
Purchase of property, plant and equipment, intangible assets, capital work-in-progress and intangible assets under development	(2,629)	(2,659)	(3,029)	(3,335)
Proceeds from sale of property, plant and equipment	17	1	61	282
Investment in subsidiaries	(10,300)	-	-	-
Loans given to subsidiaries	(2,812)	(2,147)	-	-
Movement in other short term deposits and margin money (net)	(2,968)	3,155	(2,968)	3,157
Interest income received	86	275	95	286
<b>Net cash flows from / (used in) investing activities (B)</b>	<b>(18,606)</b>	<b>(1,375)</b>	<b>(5,841)</b>	<b>390</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>				
Proceeds from exercise of employee stock options	311	86	311	86
Proceeds from issue of shares via rights issue	24,929	-	24,929	-
Transaction costs on issue of shares	(170)	-	(170)	-
Proceeds from preferential allotment	-	1,000	-	1,000
Proceeds from non-current borrowings	1,000	-	1,000	-
Repayment of non-current borrowings	(4,926)	(5,420)	(15,790)	(6,770)
Movement in current borrowings (net)	6,148	(31,428)	5,284	(32,346)
Payment of lease liabilities including interest	(198)	(160)	(198)	(160)
Finance costs paid	(3,580)	(5,054)	(4,579)	(6,603)
<b>Net cash flow (used in) / generated from financing activities (C)</b>	<b>23,514</b>	<b>(40,976)</b>	<b>10,787</b>	<b>(44,793)</b>
<b>Net decrease in cash and cash equivalents (D) = (A)+B+C</b>	<b>(5,513)</b>	<b>2,516</b>	<b>(5,468)</b>	<b>2,495</b>
Cash and cash equivalents at the beginning of the period (E)	5,718	3,198	5,731	3,232
Effect of movements in exchange rates on cash and cash equivalents (F)	6	4	6	4
<b>Cash and cash equivalents at the end of the period (G) = (D)+(E)+(F)</b>	<b>211</b>	<b>5,718</b>	<b>269</b>	<b>5,731</b>




**Notes :**

- 1 The above audited standalone and consolidated financial results of NAACL Industries Limited ("NAACL" or the "Company") or the "Company", which have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI") were reviewed and recommended by the Audit Committee and approved by the Board of Directors in their meetings held on 4 May 2026. The Statutory Auditors have issued an unmodified opinion on the financial results for the quarter and year ended 31 March 2026.
- 2 The Consolidated Financial Results include the results of the following:
  - i) Parent:
    - a) NAACL Industries Limited, India
  - ii) Wholly Owned Subsidiaries:
    - a) LR Research Laboratories Private Limited, India
    - b) Nagarjuna Agrichem (Australia) Pty Limited, Australia
    - c) NAACL Spec-Chem Limited, India
    - d) NAACL Multichem Private Limited, India
    - e) NAACL Industries (Nigeria) Limited, Nigeria
    - f) NAACL Agri-Solutions Private Limited
  - iii) Associate:
    - a) Nasense Labs Private Limited, India
- 3 Pursuant to (i) share purchase agreement dated 12 March 2025 among Coromandel International Limited ("CIL"), KLR Products Limited, Mrs. Kanumuru Lakshmi Raju and Bright Town Investment Advisor Private Limited ("Promoter SPA"); (ii) share purchase agreement dated 12 March 2025 among CIL and M/s. Agro Life Science Corporation; (iii) share purchase agreement dated 12 March 2025 among CIL and M/s. Krishi Rasayan Exports Private Limited; and (iv) the mandatory open offer made by CIL to the public shareholders of NAACL in accordance with the provisions of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 ("Takeover Regulations"), CIL has acquired in aggregate 10,69,12,581 equity shares of NAACL representing 53.08% of the voting share capital of NAACL. Consequently, CIL has acquired control of NAACL and became the promoter of NAACL and NAACL has become a subsidiary of CIL with effect from 8 August 2025.
- 4 The Company has made a rights issue of 32,501,851 fully paid up Equity Shares of face value of ₹ 1 each for a price of ₹ 76.7 per rights equity share (including a premium of ₹ 75.7 per rights equity share) aggregating up to ₹ 24,771 lakhs (net of issue expenses of ₹ 158 lakhs) for repayment of debt of ₹ 18,700 lakhs and general corporate purposes of ₹ 6,071 lakhs and allotted equity shares on 31 December 2025. These funds has been utilised for the purpose it was raised and unutilized amount of ₹ 3,080 lakhs is deposited in earmarked bank account, pending utilization for general corporate purpose.
- 5 Earnings per share for all the comparative periods have been retrospectively adjusted for the effects of the rights issue.
- 6 Pursuant to a strategic review by the Board of the Company, the Company has decided to discontinue certain products under development and other investments, which have been disclosed as exceptional items during the year ended 31 March 2026. Exceptional item of ₹ 2,926 lakhs for year ended 31 March 2025 pertains to favourable ruling related to Company's insurance claim proceeding.
- 7 The Company/ Group is primarily engaged in the farm inputs, which in the context of Ind AS 108 "Operating Segments" is considered the only significant business segment.
- 8 The Company has allotted 165,000 equity shares during the quarter ended 31 March 2026 pursuant to exercise of stock options.
- 9 On 21 November 2025, the Government of India notified four labour codes - effective immediately, replacing 29 existing labour laws. The implementation of the Labour Codes does not have significant impact on the provision for defined benefit obligation. The Company continues to monitor the finalisation of the Labour Codes, and will incorporate appropriate accounting treatment based on the developments as required.
- 10 The figures of the quarter ended 31 March 2026 and 31 March 2025 are the balancing figures between the audited figures of the full financial year ended 31 March 2026 and 31 March 2025 respectively, and the year to date figures upto third quarter ended 31 December 2025 and 31 December 2024, respectively which were subjected to a limited review.

Place : Hyderabad  
Date : 4 May 2026



  
Dr. Raghuram Devarakonda  
Managing Director & CEO





**NACL Industries Limited**

Regd. Office: Coromandel House, 1-2-10, Sardar Patel Road, Secunderabad, Hyderabad 500003, Telangana, India  
 Phone:040-24405100,Fax:040-23358062,E-mail:info@naclind.com,Website:www.naclind.com  
 CIN:L24249TG1986PLC016607

**Extract of the Statement of Standalone and Consolidated Financial Results for the Quarter and Year ended 31 March 2026**

Sl. No.	Particulars	Standalone				Consolidated			
		Quarter ended 31 March 2026	Quarter ended 31 March 2025	Year ended 31 March 2026	Year ended 31 March 2025	Quarter ended 31 March 2026	Quarter ended 31 March 2025	Year ended 31 March 2026	Year ended 31 March 2025
		(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)
1	Total Income from Operations	33,529	20,556	1,51,530	1,26,177	36,256	20,205	1,58,727	1,24,256
2	Net Profit/ (loss) for the period (before Tax & Exceptional and/or Extraordinary items)	(119)	(8,423)	4,008	(12,576)	(119)	(9,496)	2,702	(14,850)
3	Net Profit/ (loss) for the period before Tax, (after Exceptional and/or Extraordinary items)	(119)	(5,497)	2,980	(9,650)	(119)	(6,570)	957	(11,924)
4	Net Profit/ (loss) for the period after Tax, (after Exceptional and/or Extraordinary items)	(76)	(4,111)	2,274	(7,308)	(86)	(5,000)	457	(9,213)
5	Total Comprehensive Income/ (loss) for the period [Comprising Profit/ (loss) for the period (after tax) and Other Comprehensive Income/ (loss) (after tax)]	(47)	(4,385)	2,258	(7,627)	(51)	(5,276)	447	(9,532)
6	Paid-up equity share capital (Face value of ₹ 1. per equity share)	2,342	2,012	2,342	2,012	2,342	2,012	2,342	2,012
7	Earnings per Share								
a)	Basic	(0.03)	(1.90)	1.04	(3.39)	(0.04)	(2.31)	0.21	(4.27)
b)	Diluted	(0.03)	(1.90)	1.04	(3.39)	(0.04)	(2.31)	0.21	(4.27)

**Notes:**

- The above audited standalone and consolidated financial results of NACL Industries Limited ("NACL" or the "Company"), were reviewed and recommended by the Audit Committee and approved by the Board of Directors in their meetings held on 4 May 2026. The Statutory Auditors have issued an unmodified opinion on the financial results for the quarter and year ended 31 March 2026.
- The above is an extract of the detailed format of Statement of Standalone and Consolidated Financial Results for the Quarter and Year ended 31 March 2026 filed with BSE Limited & NSE Limited under Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of Statement of Standalone and Consolidated Financial Results for the Quarter and Year ended 31 March 2026 is available on the website of BSE & NSE Limited and Company's website at [www.naclind.com](http://www.naclind.com)

Place : Hyderabad  
 Date : 04 May 2026



**Dr. Raghuram Devarakonda**  
 Managing Director & CEO

*D. Raghuram*

*Raghuram*